Edesa Biotech (EDSA) Long-Term Debt Issuances (2020)
Edesa Biotech (EDSA) posted Long-Term Debt Issuances of $15346.0 for Q4 2020, up 17338.64% sequentially from $88.0 in Q3 2020.
Edesa Biotech (EDSA) Long-Term Debt Issuances (2020) Analysis & Trends
Edesa Biotech has reported Long-Term Debt Issuances for 1 years, with the latest figure at $15346.0 in Q4 2020.
- Quarterly Long-Term Debt Issuances changed N/A year-over-year to $15346.0 in Q4 2020, while the trailing twelve-month figure through Jun 2023 was $15346.0 (changed N/A YoY) and the FY2024 annual result came in at $29532.0, changed N/A from the prior year.
- Long-Term Debt Issuances advanced to $15346.0 in Q4 2020 per EDSA's latest filing, from $88.0 in the prior quarter.
- Over five years, Long-Term Debt Issuances peaked at $15346.0 in Q4 2020 and troughed at $88.0 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Edesa Biotech | 40.44 Mn | 40.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 15,346.00 |
| Dec 31, 2020 | 15,346.00 |
| Sep 30, 2020 | 88.00 |
| Sep 30, 2020 | 88.00 |